OSI PHARMACEUTICALS, INC. CONSULTING AND CONFIDENTIAL DISCLOSURE AGREEMENTConsulting and Confidential Disclosure Agreement • August 7th, 2009 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
This Consulting and Confidential Disclosure Agreement (“Agreement”) is effective as of the date of the last party to sign below (“Effective Date”) by and between OSI Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “OSI”), having executive offices at 41 Pinelawn Road, Melville, New York 11747, and Daryl Granner, M.D., an individual (“Consultant”).
Matrix Portfolio No.1 Limited acting in its capacity as General Partner of the Matrix Portfolio No.1 Limited Partnership (1) Oxford Real Estate Owner No 2 Limited (2)Osi Pharmaceuticals Inc • August 7th, 2009 • In vitro & in vivo diagnostic substances • England and Wales
* Page references provided in this Table of Contents refer solely to this Exhibit 10.3 as provided in this Quarterly Report on Form 10-Q. The remainder of this Exhibit 10.3 appears in the same form as the executed agreement.
PURCHASE AND SALE AGREEMENT between MILLSAW REALTY L.P. SELLER, and OSI PHARMACEUTICALS, INC. BUYER. Premises: July 6, 2009Purchase and Sale Agreement • August 7th, 2009 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
THIS PURCHASE AND SALE AGREEMENT (this “Agreement”), made as of the 6th day of July 2009, between Millsaw Realty L.P., a Delaware limited partnership having an office at One Stamford Forum, Stamford, Connecticut (“Seller”) and OSI Pharmaceuticals, Inc., a Delaware corporation, having an office at 41 Pinelawn Road, Melville, New York (“Buyer”).
